San Diego, CA, October 05, 2013 --(PR.com
)-- Lisa Butterfield, Associate Professor of Medicine and Director of UPCI Immunologic Monitoring & Cellular Products Laboratory at the University of Pittsburgh, will give a presentation on “Immune Biomarkers in Cancer Immunotherapy” at the 6th Immunotherapeutics & Immunomonitoring Conference to be held in San Diego, CA on January 29-31, 2014 by GTC.
Predictive and prognostic biomarkers of clinical response to immunotherapy have been sought for many years. Recent trials have sometimes yielded promising prognostic biomarkers for further testing, but few reproducible and reliable biomarkers have been identified, and there is little information to date for identifying patients who may benefit at baseline from a specific treatment approach. Several immunotherapy groups have been working together to identify hurdles and solve technical problems to move the field forward. The following topics will be addressed:
• Hurdles in cancer immunotherapy biomarker development
• Recommendations for immunologic monitoring of clinical trials
• Recent successes in immune biomarker assessments
Network with leading experts from the scientific and clinical arenas as well as investigators in industry to discuss novel findings and developments in immunological assays and procedures. Learn about recent advances in immunotherapy, as they relate to various modalities, specific cancers, cell subsets, and animal models. Discuss potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories.
This conference is part of the Novel Immunotherapeutics Summit 2014, which includes three additional parallel conferences shown below:
12th Cytokines & Inflammation
2nd Immunogenicity & Immunotoxicity
Inaugural Innate Immunity
For more information, please visit www.gtcbio.com